Skip to main content

Targeting fusion RNAs in metastatic tumors

Intervista a Nolan Priedigkeit By 8 Dicembre 2023Dicembre 9th, 2023No Comments

Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable. Researchers are exploring innovative strategies using gene therapy techniques to target fusion RNA sequences directly. Is the gene therapy revolution knocking on our door? We asked Nolan Priedigkeit (Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, Boston), that we met at San Antonio Breast Cancer Symposium 2023.